Literature DB >> 25031286

Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease.

Eric McDade1, Albert Kim2, Jeffrey James2, Lei K Sheu2, Dora Chieh-Hsin Kuan2, Davneet Minhas2, Peter J Gianaros2, Snezana Ikonomovic2, Oscar Lopez2, Beth Snitz2, Julie Price2, Jim Becker2, Chet Mathis2, William Klunk2.   

Abstract

OBJECTIVE: To evaluate alterations in cerebral blood flow (CBF) using arterial spin-labeled MRI in autosomal dominant Alzheimer disease (ADAD) mutation carriers (MCs) in relation to cerebral amyloid and compared with age-matched healthy controls.
BACKGROUND: Recent work has identified alterations in CBF in elderly subjects with mild cognitive impairment and Alzheimer dementia using MRI. However, similar studies are lacking in ADAD. Subjects with ADAD are generally free of significant vascular disease and offer the opportunity to measure CBF early in the pathologic process before significant symptom onset when unique markers might be identified.
METHODS: Fourteen MCs (presenilin-1 and amyloid beta precursor protein) (Clinical Dementia Rating [CDR] 0 = 9, CDR 0.5 = 4, CDR 1 = 1) and 50 controls underwent 3-tesla pulsed arterial spin-labeled MRI. SPM8 was used to test the effect of MC status at the voxel level on CBF before and after controlling for age and CDR.
RESULTS: MCs had decreased perfusion in the caudate and inferior striatum bilaterally even after controlling for age and CDR. In MCs, separate areas of decreased CBF were associated with increasing cerebral amyloid and to decreased performance of attention and executive function.
CONCLUSIONS: Early CBF changes were identified in asymptomatic and mildly symptomatic subjects with ADAD, particularly in the anterior striatum. Furthermore, amyloid deposition was associated with decreased CBF in a number of regions including anterior and posterior cortical areas. Both amyloid and decreased CBF were associated with declines primarily in executive cognitive function.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25031286      PMCID: PMC4150128          DOI: 10.1212/WNL.0000000000000721

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Comparison of quantitative perfusion imaging using arterial spin labeling at 1.5 and 4.0 Tesla.

Authors:  Jiongjiong Wang; David C Alsop; Lin Li; John Listerud; Julio B Gonzalez-At; Mitchell D Schnall; John A Detre
Journal:  Magn Reson Med       Date:  2002-08       Impact factor: 4.668

2.  Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer's disease.

Authors:  Ozioma C Okonkwo; Guofan Xu; Jennifer M Oh; N Maritza Dowling; Cynthia M Carlsson; Catherine L Gallagher; Alex C Birdsill; Matthew Palotti; Whitney Wharton; Bruce P Hermann; Asenath LaRue; Barbara B Bendlin; Howard A Rowley; Sanjay Asthana; Mark A Sager; Sterling C Johnson
Journal:  Cereb Cortex       Date:  2012-12-12       Impact factor: 5.357

3.  Regional cerebral perfusion in patients with Alzheimer's disease and mild cognitive impairment: effect of APOE epsilon4 allele.

Authors:  Sun Mi Kim; Min Ji Kim; Hak Young Rhee; Chang-Woo Ryu; Eui Jong Kim; Esben Thade Petersen; Geon-Ho Jahng
Journal:  Neuroradiology       Date:  2012-07-25       Impact factor: 2.804

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  Use of total cerebral blood flow as an imaging biomarker of known cardiovascular risks.

Authors:  J Richard Jennings; Alicia F Heim; Dora Chieh-Hsin Kuan; Peter J Gianaros; Matthew F Muldoon; Stephen B Manuck
Journal:  Stroke       Date:  2013-07-23       Impact factor: 7.914

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree.

Authors:  A M Kennedy; S K Newman; R S Frackowiak; V J Cunningham; P Roques; J Stevens; D Neary; C J Bruton; E K Warrington; M N Rossor
Journal:  Brain       Date:  1995-02       Impact factor: 13.501

8.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Cerebral blood flow links insulin resistance and baroreflex sensitivity.

Authors:  John P Ryan; Lei K Sheu; Timothy D Verstynen; Ikechukwu C Onyewuenyi; Peter J Gianaros
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

10.  Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease.

Authors:  Tammie L S Benzinger; Tyler Blazey; Clifford R Jack; Robert A Koeppe; Yi Su; Chengjie Xiong; Marcus E Raichle; Abraham Z Snyder; Beau M Ances; Randall J Bateman; Nigel J Cairns; Anne M Fagan; Alison Goate; Daniel S Marcus; Paul S Aisen; Jon J Christensen; Lindsay Ercole; Russ C Hornbeck; Angela M Farrar; Patricia Aldea; Mateusz S Jasielec; Christopher J Owen; Xianyun Xie; Richard Mayeux; Adam Brickman; Eric McDade; William Klunk; Chester A Mathis; John Ringman; Paul M Thompson; Bernardino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Stephen Salloway; Stephen Correia; Peter R Schofield; Colin L Masters; Christopher Rowe; Victor L Villemagne; Ralph Martins; Sebastien Ourselin; Martin N Rossor; Nick C Fox; David M Cash; Michael W Weiner; David M Holtzman; Virginia D Buckles; Krista Moulder; John C Morris
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-05       Impact factor: 11.205

View more
  18 in total

1.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

2.  Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP.

Authors:  Giuseppe Faraco; Laibaik Park; Ping Zhou; Wenjie Luo; Steven M Paul; Josef Anrather; Costantino Iadecola
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

3.  The key role of transient receptor potential melastatin-2 channels in amyloid-β-induced neurovascular dysfunction.

Authors:  L Park; G Wang; J Moore; H Girouard; P Zhou; J Anrather; C Iadecola
Journal:  Nat Commun       Date:  2014-10-29       Impact factor: 14.919

4.  Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.

Authors:  Dana L Tudorascu; Stewart J Anderson; Davneet S Minhas; Zheming Yu; Diane Comer; Patrick Lao; Sigan Hartley; Charles M Laymon; Beth E Snitz; Brian J Lopresti; Sterling Johnson; Julie C Price; Chester A Mathis; Howard J Aizenstein; William E Klunk; Benjamin L Handen; Brad T Christian; Ann D Cohen
Journal:  Neurobiol Aging       Date:  2018-09-27       Impact factor: 4.673

5.  Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid.

Authors:  Daniel Albrecht; A Lisette Isenberg; Joy Stradford; Teresa Monreal; Abhay Sagare; Maricarmen Pachicano; Melanie Sweeney; Arthur Toga; Berislav Zlokovic; Helena Chui; Elizabeth Joe; Lon Schneider; Peter Conti; Kay Jann; Judy Pa
Journal:  J Neurosci       Date:  2020-10-12       Impact factor: 6.167

6.  Rate of Perceived Exertion and Cardiorespiratory Fitness in Older Adults with and without Alzheimer's Disease.

Authors:  Andrea Bevan; Eric Vidoni; Amber Watts
Journal:  Int J Exerc Sci       Date:  2020-02-01

7.  Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition.

Authors:  Ann D Cohen; Eric McDade; Brad Christian; Julie Price; Chester Mathis; William Klunk; Benjamin L Handen
Journal:  Alzheimers Dement       Date:  2018-03-01       Impact factor: 21.566

8.  Remote ischemic conditioning: a treatment for vascular cognitive impairment.

Authors:  David C Hess; Mohammad B Khan; Nasrul Hoda; John C Morgan
Journal:  Brain Circ       Date:  2015-12-31

9.  Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.

Authors:  Jonathan Vöglein; Katrina Paumier; Mathias Jucker; Oliver Preische; Eric McDade; Jason Hassenstab; Tammie L Benzinger; James M Noble; Sarah B Berman; Neill R Graff-Radford; Bernardino Ghetti; Martin R Farlow; Jasmeer Chhatwal; Stephen Salloway; Chengjie Xiong; Celeste M Karch; Nigel Cairns; Hiroshi Mori; Peter R Schofield; Colin L Masters; Alison Goate; Virginia Buckles; Nick Fox; Martin Rossor; Patricio Chrem; Ricardo Allegri; John M Ringman; Günter Höglinger; Harald Steiner; Marianne Dieterich; Christian Haass; Christoph Laske; John C Morris; Randall J Bateman; Adrian Danek; Johannes Levin
Journal:  Brain       Date:  2019-05-01       Impact factor: 15.255

10.  Lower cerebral perfusion is associated with tau-PET in the entorhinal cortex across the Alzheimer's continuum.

Authors:  Anna Rubinski; Duygu Tosun; Nicolai Franzmeier; Julia Neitzel; Lukas Frontzkowski; Michael Weiner; Michael Ewers
Journal:  Neurobiol Aging       Date:  2021-02-10       Impact factor: 5.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.